期刊文献+

罗格列酮联合二甲双胍快速改善胰岛素抵抗

下载PDF
导出
摘要 目的:为超重/或肥胖的2型糖尿病患者探索理想的治疗方案。方法:80例经生活干预加足量二甲双胍治疗2月以上、血糖控制不理想的2型糖尿病患者,随机加用罗格列酮和安慰剂治疗12周,观察两组间治疗前后空腹血糖、餐后2h血糖、糖化血红蛋白及胰岛素抵抗的变化。结果:12周后,罗格列酮治疗组较安慰剂组的空腹血糖、糖化血红蛋白、胰岛素抵抗指数均有显著降低。结论:罗格列酮联合二甲双胍可以快速改善超重/或肥胖的2型糖尿病患者的胰岛素抵抗,是此类患者的理想治疗方案。
出处 《包头医学院学报》 CAS 2010年第5期64-65,共2页 Journal of Baotou Medical College
  • 相关文献

参考文献3

二级参考文献31

  • 1王鸿燕,邹大进,林朱森.正常人血清脂联素水平及其影响因素[J].上海医学,2005,28(1):64-65. 被引量:16
  • 2刘岩,邹大进,李慧,陈月,丁继军,郑兴,郭鹏飞.低脂联素血症是冠状动脉粥样硬化严重程度的重要标志[J].中华内分泌代谢杂志,2005,21(1):5-8. 被引量:111
  • 3Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care,2002, 8 (11 Suppl): S283-S292; quizS293-S296.
  • 4Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Central adiposity determines prevalence differences of the metabolic syndrome.Obes Res, 2003,11:1480-1487.
  • 5Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med, 2003,157: 821-827.
  • 6Von-Eyben FE, Mouritsen E, Holm J, et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord, 2003,27: 941-949.
  • 7Han TS, Williams K, Sattar N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res,2002,10:923-931.
  • 8Steinberger J. Diagnosis of the metabolic syndrome in children. Curr Opin Lipidol, 2003,14: 555-559.
  • 9Maison P, Byrne CD, Hales CN, et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care,2001,24:1758-1763.
  • 10Lee ZS, Critchley JA, Chan JC, et al. Obesity is the key determinant of cardiovascular risk factors in the Hong Kong Chinese population:cross-sectional clinic-based study. Hong Kong Med J,2000,6: 13-23.

共引文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部